GoDubai
  
  
  
  
Citylife > Press Release
  Home Contact us Add to Favourites
Most Recent Postings
More Press Releses
Featured Sections

Event Finder
A daily roundup of exhibitions, promotions and other events in Dubai and the rest of the Emirates.
Submit an Event
Latest Dubai Press Releases >> Healthcare, Fitness and Medicine

 
  Share
  • The pharmaceutical leader conducted an industry-first head-to-head study of two biologic therapies commonly used to treat the illness: vedolizumab and adalimumab
  • Vedolizumab was found to be superior in achieving clinical remission and mucosal healing at week 52
  • Study focused on patients with moderately to severely active ulcerative colitis  
Dubai, UAE, March 11, 2019:   Global biopharmaceutical company Takeda today announced the results of its pioneering VARSITY study into the effectiveness of two common therapies used to treat Ulcerative Colitis. Shared at the 14th Congress of the European Crohn's and Colitis Organization (ECCO) in Copenhagen Denmark, the findings showed that the use of vedolizumab – a gut-selective biologic treatment, was more effective overall at tackling the illness when compared to adalimumab– a common anti-tumor therapy.
 
Specifically, the study found that by week 52 of treatment among patients with moderate to severely active ulcerative colitis, 31.3 percent of those receiving vedolizumab intravenously experienced clinical remission*, compared to 22.5 percent of patients receiving adalimumab via injection at week 52. In addition, 39.7 percent of patients treated with vedolizumab recorded mucosal healing** - a slowing of the disease's progression, compared to 27.7 percent of those receiving adalimumab.
 
A non-statistically significant difference in favor of adalimumab was seen among patients who stopped taking oral corticosteroids - steroid hormones that are usually produced in the adrenal gland and were in clinical remission*** at week 52. Meanwhile, although the study was not conducted to compare the safety of the two treatments, patients treated with vedolizumab had a lower rate (62.7 percent) of adverse effects over 52 weeks compared to patients receiving adalimumab treatment (69.2 percent). Those treated with vedolizumab recorded a lower rate of infection (33.5 percent) compared to patients treated with adalimumab (43.5 percent). The rate of serious adverse events was also lower in vedolizumab-treated patients than adalimumab (11.0% vs. 13.7% respectively).
 
“The VARSITY study addresses critical questions concerning the selection of biologic therapy in ulcerative colitis. The goal of treatment of this disease is to achieve clinical remission and mucosal healing, and these results clearly highlight the benefits seen with vedolizumab versus adalimumab towards these important outcomes.” said Dr. Bruce E. Sands, primary investigator of the VARSITY study and Chief of both the Dr. Henry D. Janowitz Division of
Gastroenterology at Mount Sinai Hospital, and the Icahn School of Medicine at Mount Sinai in New York.
 
Jeff Bornstein, M.D., Executive Medical Director, Takeda added, “The study gives physicians invaluable knowledge towards treatment decisions when starting biologic therapy. This is also the first time we have seen a direct comparison between two medicines with distinct modes of action in ulcerative colitis. This is an exciting time in the landscape of ulcerative colitis treatment, as head-to-head clinical data has not previously been available to guide treatment decisions around biologic therapies.”
 
The VARSITY study comprised a random selection of 769 patients, all of whom had shown an inadequate response with, loss of response to, or intolerance to corticosteroids, immunomodulators, or one TNFα-antagonist other than adalimumab before being enrolled. 
 
Patients were randomly placed into one of two treatment groups - vedolizumab IV and placebo SC or adalimumab SC and placebo IV. Patients in the vedolizumab group were administered 300 mg of vedolizumab IV at weeks 0, 2, 6 and every 8 weeks after until week 46, along with placebo SC at week 0 and every 2 weeks until week 50. The adalimumab group were administered 160 mg of adalimumab SC at week 0, 80 mg at week 2 and 40 mg every 2 weeks until week 50, along with placebo IV at weeks 0, 2, 6 and every 8 weeks thereafter until week 46. Dose escalation was not permitted in either treatment arm during the study.1, 



Posted by : GoDubai Editorial Team
Viewed 6027 times
Posted on : Monday, March 11, 2019  
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of GoDubai.com.
Previous Story : A New Manufacturing Approach to Optical Transceivers
Next Story : RAK Hospital wins MRM business award for the 2nd time
Email this article Print this article

Share this article with your friends and followers
NewsVine

Comments

Back to Top  
Most Viewed Press Release posted in the last 7 days
Tissot Introduces Chrono XL 3x3 Street Basketball Special Collection
Hackket's Bags of Style
Chloé Launches The New Cloud-shaped “rosie” Sunglasses
BYS COSMETICS Now in UAE
Saint Honore
Introducing the Swim and Beachwear Summer Collection from Marks & Spencer
Max Mara Resort 2020 Collection
VBQ-presskit-denim-70s Capsule
New Land Rover Defender Completes Tusk Testing to Support Lion Conservation in Kenya
OMEGA Rocket Engine - Introducing the Master Chronometer Calibre 3861
Ministry of State for FNC Affairs Launches Forum Titled ‘Political Empowerment i...
Natural and gentle haircare essentials for your little ones from Fifi & Friends'
Eberhard & Co. Alfa Romeo Limited Edition
Jaguar Land Rover & Bmw Group Announce Collaboration for Next Generation Electri...
Rado Captain Cook Automatic Limited Edition with travel case'
Electricity Most Searched Fuel Energy Term Online in UAE
Britain's Greatest Test Driver, Norman Dewis Obe, Passes Away
Kickstart your summer workout with Ibn Battuta Mall's free indoor family Fun Run
Vincitore Realty sells out 108 homes in the Dh375 million Benessere project in j...
The Gucci Runway Makeup Looks for Cruise 2020
Aston Martin Produces First Cars at St Athan
Certina DS PH200M collection'
UAE and Oman bodies sign MoU to jointly promote Internal Auditing
Backseat battles: kids driving their parents to distraction – and danger on the ...
Sony World Photography Awards Reveals New Categories for 2020 and Latest Sony Gr...
BMW Group and Jaguar Land Rover announce collaboration for next-generation elect...
The Chaumet Garden of Earthly Delights
The Economic Times recognizes Malabar Gold & Diamonds as one of the Best Brands 2019
Choose the perfect fragrance this Father's Day with Rasasi
ZAAM Launches a spin on their iconic Polyhedron bag
From the Big Screen to Real Life: Tag Heuer Unveils New Monaco Limited Edition ...
Historic Opening of Coca-cola Arena Gets the Seal of Approval From Thousands of Fans
Jennifer Lopez in Ralph Lauren
Jaquet Droz Unveils Its 2019 Novelties at Dubai Mall
The SS19 Exclusive Edit From Etoile “La Boutique''
Happy Father's Day with Tonda 1950 Skeleton
CEO of Etihad ESCO, Ali Al Jassim's Statement on World Environment Day 2019
Empower launches summer campaign to reduce district cooling consumption for the ...
Restoration by Parmigiani Fleurier
Sharjah Chamber to Take Part in the 11th Edition of the World Chambers Congress ...
Dubai Cares supports 3-year teacher training program in Ghana to boost early chi...
Team Abu Dhabi award Cappellini new long-term contract
Dp World, UAE Region's Strategic Solutions Boost the Automotive Sector
Resolution: Airlines Urge Governments to Adhere to Global Slot Allocation Guidelines
Dan Martin Returns to the Road to Lead UAE Team Emirates at the Criterium Du Dauphine
Celebrate Father's Day with Marks & Spencer
Constructsteel Conference to take place in the Middle East for the first time
Emirates NBD highlights commitment to preserving marine biodiversity on World Oc...
Ibn Battuta Mall Eid Al Fitr Celebrations
Eberhard & Co. Alfa Romeo Limited Edition'